2025 Critical Care Congress Skip to main content
2025 Critical Care Congress Main banner
Final Program


Endocrine

Critical Care and Perioperative Implications of New Diabetic Medications

Management of Sodium-Glucose Transport Protein 2 Inhibitors in Critically Ill Patients

Tuesday, February 25, 2025
9:50am - 10:05am Eastern Time
Location: Valencia Ballroom/415A
Disclosure(s):
Adham Mohamed, PharmD, BCPS, BCCCP: No relevant financial relationship(s) to disclose.

The use of SGLT-2 Inhibitors has increased in patients with diabetes and heart failure. Several studies have observed reduced risk of adverse cardiovascular events with the use of SGLT-2 inhibitors in patients with heart failure and/or diabetes. However, SGLT-2 inhibitors carry several risks including but not limited to euglycemic diabetic ketoacidosis and life-threatening genitourinary infections. This session will provide an overview on the pharmacology and indications of SGLT-2 inhibitors, as well as their risk and management strategies of complications in critically ill patients.